Skip to Content
Merck
CN
  • B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome.

B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome.

BMC cancer (2014-08-21)
Vibeke A Ingebrigtsen, Kjetil Boye, Jahn M Nesland, Arild Nesbakken, Kjersti Flatmark, Øystein Fodstad
ABSTRACT

We have previously reported overexpression of the immunoregulatory protein B7-H3 in colorectal cancer and that nuclear expression predicted poor outcome in colon cancer patients. The present study was performed to examine the prognostic role of B7-H3 in an independent colorectal cancer cohort. Using tissue microarrays from 731 colorectal cancer patients, tumour B7-H3 expression was assessed by immunohistochemistry. Associations with clinicopathological parameters and patient outcome were investigated. Nuclear expression of B7-H3 in cancer cells was present in 27% of the samples in the total study cohort, while cytoplasmic/membrane and stromal expression was seen in 86% and 77% of the samples, respectively. Nuclear B7-H3 had no prognostic relevance in the complete outcome cohort, neither in colon cancer patients. However, nuclear B7-H3 was significantly associated with reduced recurrence-free survival in TNM stage I colorectal cancer patients. Overexpression of B7-H3 in colorectal cancer was confirmed, but in contrast to previous results, nuclear B7-H3 was not a strong prognostic biomarker in this cohort. The discrepancy might be related to the use of single-core tissue microarrays for detection of the heterogeneously expressed B7-H3, and the role of B7-H3 in colorectal cancer still needs further examination.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CD276 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
CD276 human, recombinant, expressed in E. coli, 0.5 mg protein/mL